4SC's vidofludimus fails to meet primary endpoint in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
German biotechnology firm 4SC's lead drug candidate vidofludimus has failed to meet the primary efficacy endpoint in a Phase IIb trial in rheumatoid arthritis, its lead indication. The news has wiped more than a third off the company's share price.